Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
iScience ; 25(7): 104549, 2022 Jul 15.
Article in English | MEDLINE | ID: covidwho-1945338

ABSTRACT

We report robust SARS-CoV2 neutralizing sdAbs targeting the viral peptides encompassing the polybasic cleavage site (CSP) and in the receptor binding domain (RBD) of the spike (S) protein. Both the sdAbs inhibited infectivity of the CoV2 S protein expressing pseudoviruses (LV-CoV2S). Both anti-CSP and RBD intrabodies (IB) inhibited the output of LV(CoV2 S). Anti-CSP IB altered the proteolytic processing and targeted the viral S protein for degradation. Because of cross-reactive CSPs in the entry mediators, the anti-CSP sdAb neutralized in vitro and in vivo the infectivity of SARS-CoV2 unrelated viruses such as herpes simplex virus 1 (HSV1) and pestes des petits ruminants virus (PPRV). Conversely, anti-HSV1 and anti-PPRV sera neutralized LV(CoV2 S) owing to the presence of CSP reactive antibodies indicating that a prior infection with such pathogens could impact on the pattern of COVID-19.

2.
Front Immunol ; 11: 581076, 2020.
Article in English | MEDLINE | ID: covidwho-1116666

ABSTRACT

COVID-19 has become difficult to contain in our interconnected world. In this article, we discuss some approaches that could reduce the consequences of COVID-19. We elaborate upon the utility of camelid single-domain antibodies (sdAbs), also referred to as nanobodies, which are naturally poised to neutralize viruses without enhancing its infectivity. Smaller sized sdAbs can be easily selected using microbes or the subcellular organelle display methods and can neutralize SARS-CoV2 infectivity. We also discuss issues related to their production using scalable platforms. The favorable outcome of the infection is evident in patients when the inflammatory response is adequately curtailed. Therefore, we discuss approaches to mitigate hyperinflammatory reactions initiated by SARS-CoV2 but orchestrated by immune mediators.


Subject(s)
Antibodies, Viral/administration & dosage , Antiviral Agents/administration & dosage , COVID-19/drug therapy , SARS-CoV-2/drug effects , SARS-CoV-2/physiology , Single-Domain Antibodies/administration & dosage , COVID-19/immunology , COVID-19/virology , Humans , SARS-CoV-2/genetics , SARS-CoV-2/immunology
3.
Microbes Infect ; 23(1): 104779, 2021.
Article in English | MEDLINE | ID: covidwho-1033483

ABSTRACT

The COVID-19 pandemic has raised many issues not the least of which is the reason for its high variability in consequences to the infected person. In this opinion letter, we advocate that the dose and presentation of the infecting virus is a major factor that affects whether the outcome is subclinical, tissue damaging or even lethal following infection. We briefly describe the known effects of virus dose on the course COVID-19 and discuss practical maneuvers as well as largely untested procedures that can raise the threshold dose needed to break through barriers of resistance.


Subject(s)
COVID-19/virology , SARS-CoV-2/isolation & purification , COVID-19/immunology , COVID-19/prevention & control , COVID-19 Vaccines/immunology , Galectins/pharmacology , Humans , Immunity, Innate , Pandemics , Viral Load
4.
Microbes Infect ; 22(9): 400-402, 2020 10.
Article in English | MEDLINE | ID: covidwho-651841

ABSTRACT

In this commentary we argue that the hygiene hypothesis may apply to COVID-19 susceptibility and also that residence in low hygienic conditions acts to train innate immune defenses to minimize the severity of infection. We advocate that approaches, which elevate innate immune functions, should be used to minimize the consequences of COVID-19 infection at least until effective vaccines and antiviral therapies are developed.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/epidemiology , Hygiene Hypothesis , Hygiene/economics , Life Style/ethnology , Pandemics , Pneumonia, Viral/epidemiology , Age Factors , Aged , Allergens/immunology , Betacoronavirus/immunology , COVID-19 , COVID-19 Vaccines , Child , Coronavirus Infections/ethnology , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Developed Countries/economics , Developing Countries/economics , Disease Susceptibility , Environmental Exposure/analysis , Humans , Pandemics/prevention & control , Pneumonia, Viral/ethnology , Pneumonia, Viral/immunology , Pneumonia, Viral/prevention & control , SARS-CoV-2 , Severity of Illness Index , Viral Vaccines/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL